Application of the International Prognostic Index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma

Cancer

Volumn 82, Issue 12, 1998, Pages 2439-2448

  Mok, Tony S ^a   Steinberg, Joyce ^a   Chan, Anthony T ^a   Yeo, Winnie M ^a   Hui, P ^a   Leung, Thomas W ^a   Johnson, Philip ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapy; Chinese patients; International Prognostic Index; Non Hodgkin's lymphoma; Primary extranodal lymphoma

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CHINESE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PEYER PATCH; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; WALDEYER RING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HONG KONG; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032525808     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2439::AID-CNCR19>3.0.CO;2-Q     Document Type: Article

References (33)

1. Cowan RA, Jones M, Harris M, Steward WP, Radford JT, Wagstaff J, et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer 1989;59:276-82.
2. Hayward RL, Leonard RC, Prescott RJ. A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party. Br J Cancer 1991; 63:945-52.
3. Hoskins PJ, Ng V, Spinelli JJ, Klimo P, Connors JM. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B, J Clin Oncol 1991;9:220-6.
4. Bonadonna G, Jotti GS. Prognostic factors and response to treatment in non-Hodgkin's lymphomas [review]. Anticancer Res 1987;7:685-94.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
6. Shih LY, Liang DC. Non-Hodgkin's lymphoma in Asia. Hematol Oncol Clin N Am 1991;5:983-1001.
7. Aozasa K, Tsujimoto M, Sakurai M, Honda M, Yamashita K, Hanada M, et al. Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol 1985;21:487-92.
8. Ho FC, Todd D, Loke SB, Ng RP, Khoo RK. Clinicopathological features of malignant lymphomas in 294 Hong Kong Chinese patients: retrospective study covering an eight-year period. Int J Cancer 1984;34:143-8.
9. Fisher RI, Miller TD, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr. Southwest Oncology Group clinical trials for intermediate and high grade non-Hodgkin's lymphoma. Semin Hematol 1987;24(Suppl 1):21-5.
10. Schein PS, DeVita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, et al. Bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocyctic lymphoma. Ann Intern Med 1976;85:417-22.
11. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
12. Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL. Prognostic factors for primary gastrointestinal lymphoma. Hematol Oncol 1995;13:153-63.
13. Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YC, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-70.
14. International Classification of Diseases, 9th revision, Clinical Modification. Volume 3, 3rd edition. U.S. Department of Health and Human Services, 1989.
15. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
16. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox DR. Regression model and life tables. J R Stat Soc 1972;34:187-220.
19. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;6:693-7.
20. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-60.
21. Banfi A, Bonadonna G, Carnevali G, Oldini C, Salivi E. Preferential sites of involvement and spread in malignant lymphomas. Eur J Cancer 1968;4:319-24.
22. d'Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin's lymphomas. Eur J Cancer 1991;27:1201-8.
23. Otter R, Gerrits WBJ, Sandt MVD, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma: a survey of a population-based registry. Eur J Cancer Clin Oncol 1989;25:1203-10.
24. Salem P, Anaissie E, Allam C, Geha S, Hashimi L, Ibrahim N, et al. Non-Hodgkin's lymphomas in the Middle East: a study of 417 patients with emphasis on special features. Cancer 1986;58:1162-6.
25. Modan B, Shani M, Goldman B, Modan M. Nodal and extranodal malignant lymphomas in Israel: an epidemiological study. Br J Haematol 1996;16:53-9.
26. Hsieh CI, Su WC, Chien CH, Cuo YL, Chen TY, Kao RH, et al. Clinical characteristics of and response to combination chemotherapy and subsequent application of International Prognostic Index in non-Hodgkin's lymphoma: an experience from a medical center in Southern Taiwan. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996;12:69-82.
27. The Nationwide Lymphoma Pathology Cooperative Group (NLPCG). A retrospective histological study of 9009 cases of malignant lymphoma in China using NLPCG classification. Jpn J Clin Oncol 1985;15:645-51.
28. Dawson IM, Conner JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract: report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961;49: 80-9.
29. Issacson PG, Norton AJ. Extranodal lymphoma. Hong Kong: Churchill Livingstone, 1994:1-2.
30. Levy D, Savage D, Garrison R, Anderson K, Kannel W, Castelli W. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;59: 956-60.
31. Yeoh EK, Chang KJ. Epidemiology of viral hepatitis B infection in Hong Kong. In: Lam SK, Lai CL, Yeoh EK. Viral hepatitis infection in the western Pacific region: vaccine and control. Singapore: World Scientific, 1984;33-44.
32. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu E. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261-70.
33. Lau JY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;72:911-7.